The Characteristics of Immunoncology Drugs Appraised by NICE and SMC: A Retrospective Analysis 2012–2023

IF 2 Q3 HEALTH POLICY & SERVICES

Journal of Cancer Policy Pub Date : 2025-05-20 DOI:10.1016/j.jcpo.2025.100599

Giannis Agorastos , Elpida Pavi , Athanassios Vozikis , Kostas Athanasakis

{"title":"The Characteristics of Immunoncology Drugs Appraised by NICE and SMC: A Retrospective Analysis 2012–2023","authors":"Giannis Agorastos , Elpida Pavi , Athanassios Vozikis , Kostas Athanasakis","doi":"10.1016/j.jcpo.2025.100599","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Immunoncology has revolutionized cancer treatment by offering improved survival and quality of life. This study aimed to explore the characteristics of NICE and SMC’s decisions for the reimbursement of immunoncology drugs, within the healthcare systems of the UK & Wales and Scotland respectively.</div></div><div><h3>Methods</h3><div>The classification of the Cancer Research Institute was used, to identify immunoncology drugs. A systematic search of publicly available HTA decisions on immunoncology drugs was performed, taking into account technology appraisals conducted from 2012 to 2023. Data on drug-indication pairs, recommendation status and ICER for both NICE and SMC appraisals, were extracted in standardized tables. A retrospective analysis of the reviewed decisions was conducted.</div></div><div><h3>Results</h3><div>A total of 58 NICE and 57 SMC appraisals were analyzed, revealing that most decisions were positive or optimised/restricted (91.4 % and 87.7 %, respectively). Lung cancer and melanoma were the most frequently appraised indications. More than half of the appraisals (53.4 % for NICE and 61.4 % for SMC) reported ICERs above £ 30,000 per QALY. Patient group submissions were included in 89.7 % of NICE and all SMC decisions, reflecting the agencies' commitment to incorporating patient perspectives.</div></div><div><h3>Policy summary</h3><div>The number of immunoncology drugs assessed by NICE and SMC has increased significantly in the latest years, reflecting their expanding use across a broad range of cancer indications. This study highlights the high acceptance rates of immunoncology therapies appraised by both agencies, as well as the link between high ESMO-MCBS score (for both curative and non-curative settings) and positive or optimised/restricted coverage recommendations. By exploring the characteristics of immunoncology drugs appraisals, the analysis provides insights into the evolving landscape of this therapeutic area.</div></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"45 ","pages":"Article 100599"},"PeriodicalIF":2.0000,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer Policy","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213538325000438","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH POLICY & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Immunoncology has revolutionized cancer treatment by offering improved survival and quality of life. This study aimed to explore the characteristics of NICE and SMC’s decisions for the reimbursement of immunoncology drugs, within the healthcare systems of the UK & Wales and Scotland respectively.

Methods

The classification of the Cancer Research Institute was used, to identify immunoncology drugs. A systematic search of publicly available HTA decisions on immunoncology drugs was performed, taking into account technology appraisals conducted from 2012 to 2023. Data on drug-indication pairs, recommendation status and ICER for both NICE and SMC appraisals, were extracted in standardized tables. A retrospective analysis of the reviewed decisions was conducted.

Results

A total of 58 NICE and 57 SMC appraisals were analyzed, revealing that most decisions were positive or optimised/restricted (91.4 % and 87.7 %, respectively). Lung cancer and melanoma were the most frequently appraised indications. More than half of the appraisals (53.4 % for NICE and 61.4 % for SMC) reported ICERs above £ 30,000 per QALY. Patient group submissions were included in 89.7 % of NICE and all SMC decisions, reflecting the agencies' commitment to incorporating patient perspectives.

Policy summary

The number of immunoncology drugs assessed by NICE and SMC has increased significantly in the latest years, reflecting their expanding use across a broad range of cancer indications. This study highlights the high acceptance rates of immunoncology therapies appraised by both agencies, as well as the link between high ESMO-MCBS score (for both curative and non-curative settings) and positive or optimised/restricted coverage recommendations. By exploring the characteristics of immunoncology drugs appraisals, the analysis provides insights into the evolving landscape of this therapeutic area.

查看原文本刊更多论文

NICE和SMC评价的免疫肿瘤药物特征：2012-2023回顾性分析

免疫肿瘤学通过提供更好的生存和生活质量彻底改变了癌症治疗。本研究旨在探讨在英国、威尔士和苏格兰的医疗保健系统内，NICE和SMC对免疫肿瘤药物报销的决定的特点。方法：采用肿瘤研究所分类，对免疫肿瘤药物进行鉴定。考虑到2012年至2023年进行的技术评估，对公开可获得的免疫肿瘤药物HTA决定进行了系统搜索。NICE和SMC评估的药物适应症对、推荐状态和ICER数据提取在标准化表格中。对审查的决定进行了回顾性分析。结果：共分析了58个NICE和57个SMC评估，显示大多数决策是积极的或优化/限制的（分别为91.4%和87.7%）。肺癌和黑色素瘤是最常见的适应症。超过一半的评估（53.4%的NICE和61.4%的SMC）报告的ICERs在每个QALY超过30,000英镑。89.7%的NICE和所有SMC决策纳入了患者组提交的意见，反映了各机构纳入患者观点的承诺。政策总结：近年来，NICE和SMC评估的免疫肿瘤药物数量显著增加，反映了它们在广泛的癌症适应症中的应用范围不断扩大。这项研究强调了两个机构评估的免疫肿瘤疗法的高接受率，以及高ESMO-MCBS评分（治疗性、非治疗性和非治疗性设置）与积极或优化/限制覆盖建议之间的联系。通过探索免疫肿瘤药物评价的特点，分析提供了对这一治疗领域不断发展的景观的见解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊